8-K: Cencora Q3 2025 Earnings Beat, Raises FY25 EPS Outlook

Cencora, Inc. reported an 8.7% year-over-year revenue increase to $80.7 billion and raised its fiscal year 2025 adjusted diluted EPS guidance to $15.85-$16.00.

Summary

• Revenue for the third fiscal quarter of 2025 increased 8.7% year-over-year to $80.7 billion.
• GAAP diluted earnings per share (EPS) was $3.52, a 45.5% increase from $2.42 in the prior year quarter.
• Adjusted diluted EPS increased 19.8% to $4.00, up from $3.34 in the prior year quarter.
• Fiscal year 2025 adjusted diluted EPS guidance was raised to a range of $15.85 to $16.00, from the previous range of $15.70 to $15.95.
• U.S. Healthcare Solutions segment revenue increased 8.5% to $72.9 billion, driven by overall market growth, including GLP-1 class products and specialty products.
• International Healthcare Solutions segment revenue increased 10.5% to $7.8 billion.
• Gross profit for the quarter was $2.9 billion, a 20.6% increase compared to the prior year, partly due to the January 2025 acquisition of Retina Consultants of America (RCA) and a LIFO credit.
• Operating income increased 29.0% to $0.9 billion (GAAP) and 20.6% to $1.1 billion (Adjusted).
• Net interest expense increased by $50.5 million to $81.8 million, primarily due to debt issued for the RCA acquisition and increased revolving credit facility borrowings.
• Diluted weighted average shares outstanding decreased 2.4% to 195.2 million, primarily due to share repurchases.

Sentiment

Score: 8

Explanation: The company reported strong Q3 results with significant year-over-year growth in revenue and EPS, and notably raised its full-year adjusted EPS and operating income guidance, indicating positive momentum despite some weakness in the International Healthcare Solutions segment.

Positives

• Strong revenue growth of 8.7% year-over-year to $80.7 billion.
• Significant increase in GAAP diluted EPS by 45.5% to $3.52.
• Robust growth in Adjusted diluted EPS by 19.8% to $4.00.
• Raised fiscal year 2025 adjusted diluted EPS guidance to $15.85-$16.00, indicating improved outlook.
• U.S. Healthcare Solutions segment showed strong revenue growth of 8.5% and operating income growth of 29.1%.
• Gross profit increased by 20.6% (GAAP) and 20.7% (Adjusted), demonstrating improved profitability.
• Operating income increased by 29.0% (GAAP) and 20.6% (Adjusted).
• Share repurchases led to a 2.4% decrease in diluted shares outstanding, benefiting per-share metrics.
• Growth in U.S. Healthcare Solutions was driven by increased sales of high-demand products like GLP-1 class drugs and specialty products.
• Successful integration of the January 2025 acquisition of Retina Consultants of America (RCA) contributed to U.S. Healthcare Solutions gross profit margin.

Negatives

• International Healthcare Solutions segment operating income decreased by 12.9% (16.2% on a constant currency basis) due to lower operating income in global specialty logistics and specialized consulting services.
• Net interest expense increased significantly by $50.5 million, primarily due to new debt issuances for the RCA acquisition and increased working capital borrowings.
• Gains from antitrust litigation settlements were lower in the current quarter ($9.5 million) compared to the prior year quarter ($51.6 million).
• Fiscal year 2025 guidance for International Healthcare Solutions segment operating income was revised to an approximate 6% decline (5% on a constant currency basis), from a previous range of 1-4% decline.

Risks

• Forward-looking statements are subject to uncertainty and changes in circumstances, and actual results may vary materially from indications.
• Assumptions and estimates underlying financial projections could prove incorrect.
• The company's results are affected by factors outside its control, such as the amounts and timing of gains from antitrust litigation settlements, LIFO expense/credit, and Turkey highly inflationary impact.
• LIFO expense (credit) is dependent on future inflation or deflation of brand and generic pharmaceuticals, which is outside the company's control.
• Acquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.
• The timing and amount of favorable and unfavorable legal settlements are unpredictable and cannot be reasonably estimated.

Future Outlook

Cencora updated its fiscal year 2025 financial guidance, primarily reflecting stronger earnings growth in the U.S. Healthcare Solutions segment. The company now expects revenue growth of approximately 9%, U.S. Healthcare Solutions segment revenue growth in the range of 9-10%, and International Healthcare Solutions segment revenue growth in the range of 6-7% (7-8% constant currency). Adjusted diluted EPS guidance has been raised to $15.85-$16.00. Adjusted consolidated operating income growth is projected at 15-16%, with U.S. Healthcare Solutions segment operating income growth at 20-21%. However, International Healthcare Solutions segment operating income is now expected to decline by approximately 6% (5% constant currency). The adjusted effective tax rate is anticipated to be 20.5-21%.

Management Comments

• "Cencora delivered strong financial results in the third fiscal quarter, driven by our pharmaceutical-centric strategy and focus on our growth priorities."
• "Our teams are fueling our growth as they identify opportunities and customer-centric solutions that strengthen our value proposition as the partner of choice."
• "We are guided by our purpose and focused on our strategic drivers of digital transformation, investing in our talent and culture, prioritizing growth-oriented investments and increasing productivity."

Industry Context

Cencora's strong performance in the U.S. Healthcare Solutions segment, driven by unit volume growth including GLP-1 class products and specialty products, indicates the company is effectively capitalizing on key trends in the pharmaceutical and healthcare sectors. The acquisition of Retina Consultants of America (RCA) further strengthens its position in the growing specialty healthcare services market, aligning with broader industry shifts towards specialized care and innovative therapies. The decline in International Healthcare Solutions operating income suggests regional or specific business challenges within the global logistics and consulting segments, contrasting with the robust domestic market.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing for direct comparison to industry standards.

Legal Proceedings

• Ongoing litigation and opioid-related expenses are factored into non-GAAP adjustments.
• Gains from antitrust litigation settlements are recognized, though lower than the prior year quarter.

Stakeholder Impact

• Shareholders are positively impacted by strong financial performance, increased EPS guidance, and the declared quarterly cash dividend of $0.55 per common share. Share repurchases also contribute to shareholder value.
• Customers, particularly care providers, benefit from the company's continued secure and reliable delivery of pharmaceuticals, healthcare products, and solutions, reinforcing Cencora's value proposition as a partner.
• Employees are impacted by the company's strategic focus on investing in talent and culture, and efforts to increase productivity.
• Pharmaceutical innovators benefit from Cencora's partnership across the value chain, facilitating and optimizing market access for therapies.

Next Steps

• Quarterly cash dividend of $0.55 per common share payable on September 3, 2025.
• Management attending Wells Fargo Healthcare Conference on September 5, 2025.
• Management attending Baird Healthcare Conference on September 9, 2025.
• Management attending Morgan Stanley Global Healthcare Conference on September 10, 2025.
• Management attending Nephron Healthcare Summit on September 16, 2025.

Key Dates

Recommendation

The company delivered robust financial performance in Q3 FY25, exceeding prior year results across key metrics like revenue, GAAP EPS, and Adjusted EPS. The significant upward revision of fiscal year 2025 adjusted diluted EPS guidance and operating income growth signals strong confidence in future performance, particularly within the high-growth U.S. Healthcare Solutions segment driven by specialty products and GLP-1 class drugs. While the International segment shows some weakness, the overall positive outlook, strategic acquisitions (RCA), and ongoing share repurchases make this a compelling investment opportunity.

Keywords

Cencora, COR, pharmaceutical solutions, healthcare, drug distribution, specialty pharma, GLP-1, earnings, Q3 2025, financial results, EPS, revenue, guidance, acquisition, Retina Consultants of America, Good Neighbor Pharmacy, investor relations